Contradiction Ends Amgen's Neulasta IP Suit, Fed. Circ. Says
Amgen can't win an infringement suit over its blockbuster anti-infection medicine Neulasta by relying on an argument it expressly disavowed at the Patent Office, the Federal Circuit said Monday....To view the full article, register now.
Already a subscriber? Click here to view full article